|
Name |
Methyl (2s)-4-Hydroxy-3-(4-Hydroxyphenyl)-2-[(4-Hydroxyphenyl)methyl]-5-Oxo-2,5-Dihydrofuran-2-Carboxylate
|
| Molecular Formula | C19H16O7 | |
| IUPAC Name* |
methyl (2S)-4-hydroxy-3-(4-hydroxyphenyl)-2-[(4-hydroxyphenyl)methyl]-5-oxofuran-2-carboxylate
|
|
| SMILES |
COC(=O)[C@@]1(C(=C(C(=O)O1)O)C2=CC=C(C=C2)O)CC3=CC=C(C=C3)O
|
|
| InChI |
InChI=1S/C19H16O7/c1-25-18(24)19(10-11-2-6-13(20)7-3-11)15(16(22)17(23)26-19)12-4-8-14(21)9-5-12/h2-9,20-22H,10H2,1H3/t19-/m0/s1
|
|
| InChIKey |
AEKPZNDJHWFONI-IBGZPJMESA-N
|
|
| Synonyms |
(4S)-Butyrolactone I; Butyrolactone II; Methyl (2s)-4-Hydroxy-3-(4-Hydroxyphenyl)-2-[(4-Hydroxyphenyl)methyl]-5-Oxo-2,5-Dihydrofuran-2-Carboxylate; CHEBI:191395; ZINC1484020; LBU; methyl (S)-4-hydroxy-2-(4-hydroxybenzyl)-3-(4-hydroxyphenyl)-5-oxo-2,5-dihydrofuran-2-carboxylate
|
|
| CAS | NA | |
| PubChem CID | 36687796 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 356.3 | ALogp: | 2.4 |
| HBD: | 3 | HBA: | 7 |
| Rotatable Bonds: | 5 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 113.0 | Aromatic Rings: | 3 |
| Heavy Atoms: | 26 | QED Weighted: | 0.722 |
| Caco-2 Permeability: | -4.936 | MDCK Permeability: | 0.00001860 |
| Pgp-inhibitor: | 0.007 | Pgp-substrate: | 0.01 |
| Human Intestinal Absorption (HIA): | 0.011 | 20% Bioavailability (F20%): | 0.165 |
| 30% Bioavailability (F30%): | 0.717 |
| Blood-Brain-Barrier Penetration (BBB): | 0.066 | Plasma Protein Binding (PPB): | 91.41% |
| Volume Distribution (VD): | 0.365 | Fu: | 10.75% |
| CYP1A2-inhibitor: | 0.291 | CYP1A2-substrate: | 0.758 |
| CYP2C19-inhibitor: | 0.944 | CYP2C19-substrate: | 0.088 |
| CYP2C9-inhibitor: | 0.864 | CYP2C9-substrate: | 0.896 |
| CYP2D6-inhibitor: | 0.596 | CYP2D6-substrate: | 0.698 |
| CYP3A4-inhibitor: | 0.909 | CYP3A4-substrate: | 0.345 |
| Clearance (CL): | 16.049 | Half-life (T1/2): | 0.487 |
| hERG Blockers: | 0.025 | Human Hepatotoxicity (H-HT): | 0.211 |
| Drug-inuced Liver Injury (DILI): | 0.863 | AMES Toxicity: | 0.093 |
| Rat Oral Acute Toxicity: | 0.315 | Maximum Recommended Daily Dose: | 0.009 |
| Skin Sensitization: | 0.081 | Carcinogencity: | 0.328 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.079 |
| Respiratory Toxicity: | 0.028 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC003597 | ![]() |
0.786 | D00LFB | ![]() |
0.409 | ||
| ENC003721 | ![]() |
0.733 | D0Y2NE | ![]() |
0.376 | ||
| ENC000875 | ![]() |
0.670 | D09ZQN | ![]() |
0.362 | ||
| ENC002729 | ![]() |
0.670 | D0J7RK | ![]() |
0.327 | ||
| ENC002376 | ![]() |
0.656 | D06TJJ | ![]() |
0.321 | ||
| ENC002552 | ![]() |
0.656 | D0JY8T | ![]() |
0.318 | ||
| ENC002711 | ![]() |
0.643 | D04XEG | ![]() |
0.317 | ||
| ENC002705 | ![]() |
0.643 | D01XBA | ![]() |
0.315 | ||
| ENC002900 | ![]() |
0.633 | D0Y7EM | ![]() |
0.311 | ||
| ENC002561 | ![]() |
0.629 | D03UOT | ![]() |
0.306 | ||